NJ State Employees Deferred Compensation Plan maintained its stake in NeuroDerm Ltd. (NASDAQ:NDRM) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,000 shares of the biotechnology company’s stock at the end of the second quarter. NJ State Employees Deferred Compensation Plan’s holdings in NeuroDerm were worth $299,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Oppenheimer & Co. Inc. acquired a new stake in NeuroDerm during the first quarter worth about $223,000. Nationwide Fund Advisors acquired a new stake in NeuroDerm during the first quarter worth about $226,000. HighTower Advisors LLC acquired a new stake in NeuroDerm during the first quarter worth about $242,000. Bank of Montreal Can acquired a new stake in NeuroDerm during the first quarter worth about $266,000. Finally, Credit Suisse AG acquired a new stake in NeuroDerm during the first quarter worth about $282,000. Institutional investors and hedge funds own 52.82% of the company’s stock.

NeuroDerm Ltd. (NDRM) opened at 38.65 on Thursday. The company’s market cap is $1.02 billion. NeuroDerm Ltd. has a 52-week low of $15.20 and a 52-week high of $38.85. The stock has a 50 day moving average of $33.09 and a 200-day moving average of $27.30.

NeuroDerm (NASDAQ:NDRM) last released its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.13. On average, analysts forecast that NeuroDerm Ltd. will post ($2.03) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “NJ State Employees Deferred Compensation Plan Holds Position in NeuroDerm Ltd. (NASDAQ:NDRM)” was reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/10/nj-state-employees-deferred-compensation-plan-holds-position-in-neuroderm-ltd-nasdaqndrm.html.

A number of research firms have issued reports on NDRM. Zacks Investment Research cut shares of NeuroDerm from a “hold” rating to a “sell” rating in a research note on Thursday. Roth Capital cut shares of NeuroDerm from a “buy” rating to a “neutral” rating and lifted their target price for the company from $33.00 to $39.00 in a research note on Wednesday, August 2nd. BidaskClub upgraded shares of NeuroDerm from a “sell” rating to a “hold” rating in a research note on Tuesday, July 25th. Raymond James Financial, Inc. cut shares of NeuroDerm from an “outperform” rating to a “market perform” rating and set a $39.00 target price for the company. in a research note on Monday, July 24th. Finally, Deutsche Bank AG began coverage on shares of NeuroDerm in a research note on Friday, July 21st. They issued a “buy” rating and a $47.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $44.13.

NeuroDerm Company Profile

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.

Want to see what other hedge funds are holding NDRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeuroDerm Ltd. (NASDAQ:NDRM).

Institutional Ownership by Quarter for NeuroDerm (NASDAQ:NDRM)

Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.